** Shares of drug developer Pliant Therapeutics PLRX.O hit their lowest level on record at $1.59
** The company discontinues a mid-stage trial of its experimental drug bexotegrast in patients with a type of lung disease called idiopathic pulmonary fibrosis
** PLRX says the drug trial was stopped due to reports of IPF-related adverse events
** Idiopathic pulmonary fibrosis is a chronic lung disease that causes scarring and stiffening of the organ's tissue
** PLRX paused enrollment of patients in the mid-stage trial in early February, on the recommendation of an independent data safety monitoring board
** It plans to analyze complete trial data and evaluate next steps for bexotegrast's development, including additional studies testing lower doses in IPF
** The stock is down 79.3% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。